Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
Visco V, Radano I, Campanile A, Ravera A, Silverio A, Masarone D, Pacileo G, Correale M, Mazzeo P, Dattilo G, Giallauria F, Cuomo A, Mercurio V, Tocchetti CG, Di Pietro P, Carrizzo A, Citro R, Galasso G, Vecchione C, Ciccarelli M.
Visco V, et al.
ESC Heart Fail. 2022 Oct;9(5):2909-2917. doi: 10.1002/ehf2.13982. Epub 2022 Jun 15.
ESC Heart Fail. 2022.
PMID: 35702942
Free PMC article.
AIMS: The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all-cause mortality in patients with ambulatory heart failure and reduced ejection fraction ( …
AIMS: The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reduci …